Business
Physiomics Collaboration Update
Physiomics Collaboration Update.
About this update from Valirx Plc
[{"type":"text","content":"\n \nFor immediate release: 0700hrs Wednesday 12th December 2007\n\n ValiRx Plc \n\n (\"ValiRx\" or \"the Company\") \n\n Physiomics Collaboration Update - Cancer Cell Death Model Developed \n\nValiRx (AIM: VAL), the cancer therapeutics company, today announces that Phase\n1 of its collaboration with Physiomics plc (\"Physiomics\") (AIM: PYC), the\nEuropean systems biology simulation company, has been completed.\n\nUnder the collaboration, originally announced in February 2007, Physiomics' In\nSilico simulation technology has been successfully coupled with ValiRx's\nGeneICE technology to generate a cancer cell death model - the Apoptosis Model.\n\nThis model, on which ValiRx believes it should be able to secure a patent, will\nbe used to accelerate ValiRx's own internal development programmes and as an R&\nD tool to be licensed out to third parties.\n\nAlready the Apoptosis Model has helped the Company reach key decisions\nregarding GeneICE in relation to which new cancer cells to target. For example,\nit has helped support the decision to focus on specific hormone resistant\ncancers.\n\nDr Satu Vainikka, CEO of ValiRx, commented:\n\n\"Systems based biology is able not only to accelerate the R&D process but also\nimprove diagnostic and prognostic processes. We believe our Apoptosis Model\nrepresents a significant new tool for use within the pharmaceutical industry\nand has already received significant industry interest.\"\n\nDr Christophe Chassagnole, COO of Physiomics added:\n\n\"We are pleased to have successfully applied our simulation technology to\naccelerate the development of ValiRx's breakthrough GeneICE compounds. The\nrespective strengths of our technologies have synergised to produce significant\ngains and we look forward to continuing to work with ValiRx in the future.\"\n\n ---Ends--- \n\nAbout ValiRx plc\n\nValiRx is a biopharmaceutical development company that is building a portfolio\nof complementary cancer-related therapeutic and diagnostic technologies. It\ncurrently holds a worldwide exclusive license for Nucleosomics, the early stage\noncology diagnostics technology, and has majority stakes in Cronos Ltd and\nValiBIO SA:\n\n * Cronos holds worldwide exclusive licenses to two innovative and potentially\n market changing technologies, GeneICE and HyperGenomics, and is developing\n further novel cancer t...